Restatement of Previously Issued Financial Statements | Note 13 – Restatement of Previously Issued Financial Statements On April 16, 2024, the Company changed their independent PCAOB-registered accounting firm and terminated its engagement with their prior auditor. On May 3, 2024, the Securities and Exchange Commission (“SEC”) issued an order that instituted a cease-and-desist against the Company’s previous auditor, which required the Company to obtain new auditors and re-audit its financial statements for the years ended December 31, 2023 and 2022. The Company engaged a new, an independent and registered accounting firm, to re-audit the Company’s previously issued financial statements. During the Company’s re-audits, it was noted that certain transactions were not recorded in the correct period, stock compensation expense of $600,000 related to the March 7, 2023 common stock issuance was not recorded and deferred offering costs were classified as an operating activity rather than a financing activity. Expenses totaling $10,993 were originally recorded in 2023 but related to 2022 expenses. With this restatement, the transactions previously recorded in the incorrect period have been updated to the correct period, classifications on the statements of cash flow have been corrected and the stock compensation previously not recorded has been properly recorded. The following presents reconciliations of the impacted financial statement line items as filed to the restated amounts as of June 30, 2023 and for the periods then ended. The previously reported amounts reflect those included in the registration statements the Company filed with the Securities and Exchange Commission on September 19, 2023. These amounts are labeled “As Filed” in the tables below. The amounts labeled “Restatement Adjustments” represent the effects of these restatements due to the timing differences and stock compensation expense. Schedule of restatement adjustments in financial statements Statement of Operations for the Six Months Ended June 30, 2023 As Filed Restatement Adjustments As Restated Revenue $ – $ – $ – Cost of goods sold – – – Gross profit – – – Operating expenses: Research and development – – – General and administrative 1,023,433 589,007 1,612,440 Depreciation and amortization 762 – 762 Total operating expenses 1,024,195 589,007 1,613,202 Loss from operations (1,024,195 ) (589,007 ) (1,613,202 ) Other income: Interest income – – – Total other income – – – Net loss before income tax (1,024,195 ) (589,007 ) (1,613,202 ) Income tax benefit (expense) – – – Net loss $ (1,024,195 ) $ (589,007 ) $ (1,613,202 ) Net loss per share attributable to common stockholders Basic and diluted $ (0.30 ) $ (0.17 ) $ (0.47 ) Weighted average common shares outstanding Basic and diluted 3,398,470 – 3,398,470 Statements of Changes in Stockholders’ Equity – As Filed – For the Six Months Ended June 30, 2023 Series B, Preferred Stock Common Stock Additional Paid-In Stocks to be Accumulated Shares Value Shares Value Capital Issued Deficit Total Balance, December 31, 2022 140 $ 1 3,392,250 $ 33,923 $ 4,714,041 $ – $ (1,538,591 ) $ 3,209,374 Issuance of common shares – – 75,005 750 (750 ) – – – Conversion to preferred shares 50 1 (250,000 ) (2,500 ) 2,499 – – – Net loss – – – – – – (1,024,195 ) (1,024,195 ) Balance, June 30, 2023 190 $ 2 3,217,255 $ 32,173 $ 4,716,540 $ – $ (2,562,786 ) $ 2,185,929 Statements of Changes in Stockholders’ Equity – Restatement Adjustments – For the Six Months Ended June 30, 2023 Series B, Preferred Stock Common Stock Additional Paid-In Stocks to be Accumulated Shares Value Shares Value Capital Issued Deficit Total Balance, December 31, 2022 – $ – – $ – $ – $ – $ (10,993 ) $ (10,993 ) Issuance of common shares – – – – 600,000 – – 600,000 Conversion to preferred shares – – – – – – – – Net loss – – – – – – (589,007 ) (589,007 ) Balance, June 30, 2023 – $ – – $ – $ 600,000 $ – $ (600,000 ) $ – Statements of Changes in Stockholders’ Equity – As Restated – For the Six Months Ended June 30, 2023 Series B, Preferred Stock Common Stock Additional Paid-In Stocks to be Accumulated Shares Value Shares Value Capital Issued Deficit Total Balance, December 31, 2022 140 $ 1 3,392,250 $ 33,923 $ 4,714,041 $ – $ (1,549,584 ) $ 3,198,381 Issuance of common shares – – 75,005 750 599,250 – – 600,000 Conversion to preferred shares 50 1 (250,000 ) (2,500 ) 2,499 – – – Net loss – – – – – – (1,613,202 ) (1,613,202 ) Balance, June 30, 2023 190 $ 2 3,217,255 $ 32,173 $ 5,315,790 $ – $ (3,162,786 ) $ 2,185,179 Statement of Cash Flows for the Six Months Ended June 30, 2023 As Filed Restatement Adjustments As Restated Cash flows from operating activities: Net loss $ (1,024,195 ) $ (589,007 ) $ (1,613,202 ) Depreciation 763 – 763 Stock compensation expense – 600,000 600,000 Change in assets and liabilities: Accounts receivable – – – Deferred offering costs (223,579 ) 223,579 – Other current assets 22,500 – 22,500 Accounts payable and accrued expenses (21,929 ) (10,993 ) (32,922 ) Net cash used in operating activities (1,246,440 ) 223,579 (1,022,861 ) Cash flows from investing activities Purchases of property and equipment – – – Net cash used in investing activities – – – Cash flows from financing activities: Deferred offering costs – (223,579 ) (223,579 ) Net cash provided by financing activities – (223,579 ) (223,579 ) Net increase (decrease) in cash (1,246,440 ) – (1,246,440 ) Cash, beginning of period 3,099,422 – 3,099,422 Cash, end of period $ 1,852,982 $ – $ 1,852,982 Supplemental disclosures of cash flow information: Cash paid for interest $ – $ – $ – Cash paid for income tax $ – $ – $ – |